New biotech Roxiant to tackle age-related diseases

Pharmacosmos heir Andreas Christensen, who recently founded the biotech company Roxiant, will use a protein found in people who live for an exceptionally long time to treat age-related diseases, and its first target is Huntington's disease.

Andreas Christensen has left his family's company Pharmacosmos to become CEO in the biotech business Roxiant. | Photo: Roxiant / PR

Andreas Christensen flew the nest last year, leaving Pharmacosmos, which was founded by his paternal grandfather Henry Christensen and is still run by the family, to start biotech firm Roxiant.

He still has prominent backing, however, in the form of ALK boss Rasmus Just, who is chair of the board of Roxiant, and Kasper Gubba Ørtenblad, who is a familiar face in Danish biotech. He has taken on the role of director of operations, and a handful of other medtech and pharma players are joining the team.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs